Crescent Biopharma, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.
Your own DCF model
A full discounted-cash-flow model of Crescent Biopharma, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Biotechnology
Multiples of its companies with a market value at most 60 days old, times Crescent Biopharma, Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Crescent Biopharma, Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 2.2× / 5.0× / 10.2× | — | revenue $11 M | $24 M to $110 M | 84 |
| Price to book | 3.1× / 4.5× / 12.9× | — | book equity $203 M | $621 M to $2.6 B | 69 |
Against its own history
Crescent Biopharma, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Jun 2025, each against its own median.
Price to book
0.5×Now below its median of 0.8×, in the bottom quarter of its range; range 0.4× to 4.5× over 10 months.
As of Jun 17, 2025
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $11 M | $-154 M | $-72 M | $1 M | $-72 M | — | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | — | $-38 M | $-31 M | $0 M | $-31 M | — | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $0 M | $-37 M | $-35 M | $0 M | $-35 M | — | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $0 M | $-47 M | $-46 M | $0 M | $-47 M | — | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $1 M | $-63 M | $-57 M | $0 M | $-58 M | — | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $10 M | $-51 M | $-39 M | $0 M | $-39 M | — | SEC annual report (10-K, 20-F) |